ARDT250117P25000
- 0.00
- 0.000.00%
Ardent Health Partners Newsroom
Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Ardent Health Partners, Inc. (ARDT)
J.P. Morgan Maintains Ardent Health Partners(ARDT.US) With Hold Rating, Raises Target Price to $20
JP Morgan Assumes Ardent Health Partners at Neutral, Announces Price Target of $20
Loop Capital Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $21
Ardent Health Partners, Inc. Positioned for Growth With Stable Regulatory Environment and Strategic Expansion: Analyst Confirms Buy Rating
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Announces Target Price $22
RBC Capital Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $23
Ardent Health Partners Is Maintained at Outperform by Leerink Partners
Loop Capital Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $21
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)
Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27
RBC Capital Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $23
Ardent Health Partners, Inc.: Strong Financial Performance and Growth Potential Drive Buy Rating
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating
Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27
BofA Securities Maintains Ardent Health Partners(ARDT.US) With Hold Rating, Maintains Target Price $19
Mizuho Securities Maintains Ardent Health Partners(ARDT.US) With Buy Rating
Mizuho Securities Keeps Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Ardent Health Partners Cut to Neutral From Buy by B of A Securities